Vertex beat third-quarter expectations late Monday, but an analyst says Vertex stock needs more "to drive another leg of stock upside." ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

There are questions about what to do before Trump takes office – how to change names and genders on identification cards, ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...